Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
Experts who will attend the meeting include Professor Noel Rose, Director of Autoimmune Disease Research at Johns Hopkins Hospital (USA)
In 1956, Rose and his colleagues introduced the concept of autoimmunity as a cause of disease when they discovered that the human disease chronic (Hashimoto’s) thyroiditis could be reproduced in experimental animals by immunization with thyroglobulin, a major protein constituent of the thyroid gland
Jørgen Jelstad did a great job covering the conference today!I've only just realised the iiME conference was today. I thought it was on Saturday.
Has anyone come across any more sources of info, such as twitter feeds, blogs, or forum threads?
Hi heaps - you don't have to join twitter to read it - just click on that link and you can read Jorgen's twitterfeed. He really did post some interesting stuff.can anyone update the conference on this thread.
Im not wanting to join twitter as i dont really have a need for it except for maybe this conference.
cheers!!!
ThanksHi heaps - you don't have to join twitter to read it - just click on that link and you can read Jorgen's twitterfeed. He really did post some interesting stuff.
I've only just realised the iiME conference was today. I thought it was on Saturday.
Has anyone come across any more sources of info, such as twitter feeds, blogs, or forum threads?
Rituximab is looking much more interesting. They found out why some did not respond and fixed the problem (thyroid issues) and they found a way to prevent the relapse when it starts wearing off - lower more frequent doses I think is the implication. Bye, Alex
sounds like 28 out of 30 patients in the rituximab study fit the canadian criteria - would be interesting to know if the other 2 were in the placebo or the drug group and if they were responders or not
Thanks, Bob. I'd love to read Jorgen Jelstad's pre-conference talk, “Words Matter.” It may be worth rereading his translated article, “How important is the Rituximab-study?” (http://debortgjemteinternational.wordpress.com/2011/10/30/how-important-is-the-rituximab-study/). Given the comment below, perhaps Jorgen could be moved to translate more posts:
Very informative blogpost by Norwegian journalist Jørgen Jelstad with (pre-publication) comments by Nancy Klimas, Anthony Komaroff and José Montoya on the importance of the Rituximab study. This is the first of his posts Jørgen Jelstad has translated in English. He will translate more items when he finds the time (http://www.facebook.com/permalink.php?story_fbid=180772525341643&id=122950357787779).
Thanks for this link - I'm reading it now, it's fascinating.Thanks, Bob. I'd love to read Jorgen Jelstad's pre-conference talk, “Words Matter.” It may be worth rereading his translated article, “How important is the Rituximab-study?” (http://debortgjemteinternational.wordpress.com/2011/10/30/how-important-is-the-rituximab-study/). Given the comment below, perhaps Jorgen could be moved to translate more posts: